TFX
Teleflex Incorporated NYSE$119.89
Mkt Cap $5.3B
52w Low $100.18
49.9% of range
52w High $139.67
50d MA $118.82
200d MA $118.60
P/E (TTM)
-6.0x
EV/EBITDA
25.7x
P/B
1.7x
Debt/Equity
0.9x
ROE
-22.9%
P/FCF
22.2x
RSI (14)
—
ATR (14)
—
Beta
0.83
50d MA
$118.82
200d MA
$118.60
Avg Volume
948.5K
About
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapi…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | BMO | 3.73 | 1.93 | -48.3% | 111.89 | -3.0% | +6.4% | +9.1% | +9.9% | +9.2% | +6.5% | — |
| Nov 6, 2025 | BMO | 3.38 | 3.67 | +8.6% | 124.75 | -3.7% | -13.0% | -12.3% | -13.5% | -10.0% | -10.6% | — |
| Jul 31, 2025 | BMO | 3.36 | 3.73 | +11.0% | 113.91 | +8.1% | +4.9% | +1.7% | +1.9% | +0.8% | -1.6% | — |
| May 1, 2025 | BMO | 2.88 | 2.91 | +1.0% | 137.05 | -3.0% | -8.2% | -7.8% | -10.3% | -12.0% | -10.9% | — |
| Feb 27, 2025 | BMO | 3.86 | 3.89 | +0.8% | 177.63 | -11.9% | -21.7% | -25.3% | -23.9% | -26.4% | -24.5% | — |
| Oct 31, 2024 | BMO | 3.38 | 3.49 | +3.3% | 235.22 | -11.8% | -14.5% | -10.2% | -11.9% | -13.5% | -14.2% | — |
| Aug 1, 2024 | BMO | 3.33 | 3.42 | +2.7% | 220.92 | +2.6% | +6.8% | +7.3% | +5.6% | +4.5% | +2.0% | — |
| May 2, 2024 | BMO | 3.07 | 3.21 | +4.6% | 211.54 | -1.5% | -6.1% | -4.0% | -5.0% | -4.7% | -5.2% | — |
| Feb 22, 2024 | BMO | 3.26 | 3.38 | +3.7% | 250.95 | -3.2% | -5.3% | -5.3% | -9.2% | -9.9% | -10.4% | — |
| Nov 2, 2023 | BMO | 3.27 | 3.64 | +11.3% | 187.51 | +2.4% | +11.6% | +12.5% | +13.6% | +9.2% | +6.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | Raymond James | Upgrade | Market Perform → Outperform | — | $110.49 | $114.54 | +3.7% | +5.2% | +4.0% | +8.3% | +7.2% | +6.6% |
| Feb 27 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $119.02 | $117.72 | -1.1% | +2.6% | +3.3% | +2.7% | +0.1% | -1.2% |
| Feb 27 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $119.02 | $117.72 | -1.1% | +2.6% | +3.3% | +2.7% | +0.1% | -1.2% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $111.89 | $108.54 | -3.0% | +6.4% | +9.1% | +9.9% | +9.2% | +6.5% |
| Jan 29 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $105.33 | $104.71 | -0.6% | +0.1% | -0.9% | -1.9% | -2.8% | +0.6% |
| Jan 27 | Needham | Upgrade | Hold → Buy | — | $104.20 | $104.89 | +0.7% | +0.3% | +1.1% | +1.2% | +0.2% | -0.8% |
| Dec 18 | Truist | Maintains | Hold → Hold | — | $125.10 | $125.00 | -0.1% | -0.5% | -2.6% | -0.5% | -2.2% | -2.2% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $131.25 | $130.75 | -0.4% | -0.6% | -3.0% | -3.3% | -3.5% | -4.9% |
| Nov 10 | Truist | Maintains | Hold → Hold | — | $109.40 | $110.00 | +0.5% | -1.3% | +2.6% | +1.9% | +0.0% | -2.2% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $108.51 | $108.29 | -0.2% | +0.8% | -0.5% | +3.5% | +2.7% | +0.9% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Teleflex's planned asset sales generating $1.8 billion for shareholder buybacks and debt reduction demonstrate management's commitment to value creation, supporting stock appreciation while strengthening the balance sheet.
Mar 27
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Teleflex's planned Acute Care and Urology division sale faces regulatory scrutiny with an HSR Second Request, potentially delaying the transaction and creating uncertainty around deal completion timing and valuation.
Mar 17
8-K · 7.01
! Medium
Teleflex Incorporated -- 8-K 7.01: Regulation FD Disclosure
Teleflex's voluntary disclosure suggests management is proactively communicating material information to investors, potentially signaling confidence in operations or addressing market concerns that could impact stock valuation.
Feb 26
Data updated apr 27, 2026 4:34am
· Source: massive.com